Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Minomic International Ltd. develops diagnostic and imaging products for prostate cancer and diabetes. Its MiCheck test detects a protein that is present on cancer cells by using blood sample. The company was founded in 1974 and is headquartered in Sydney, Australia.

Pieris Pharmaceuticals GmbH, part of Pieris Pharmaceuticals, Inc., is a company headquartered in Hallbergmoos, Germany. The firm operates as a biotechnology company. Stephen S. Yoder and Hitto Kaufmann are the current co-CEOs of the firm.

Nanjing Legend Biotechnology Co., Ltd. is a private company headquartered in Nanjing, China, that develops tumor cell immunotherapies.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Kochi University offers the "Kochi University App" for smartphones to make students.

Zhuhai Zhongke Advanced Technology Research Institute Co., Ltd., established on 2017-03-16, Business scope includes general items:Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Engineering and Technology Research and Experimental Development;R&D and application of cell technology;Extraction of marine bioactive substances,purification,Synthesis technology research and development;Class I Medical Device Leasing;Class II Medical Device Leasing;software development;IC Design;Integrated circuit chip design and service;Artificial intelligence industry application system integration service;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Entrepreneurial Space Services;Park Management Services;Cosmetics Wholesale;General merchandise sales;Sales of hygiene products and single-use medical products;internet sales(Except for products that require a license for sale);Sales of daily chemical products;Biochemical product technology research and development;Manufacturing of daily chemical products;Disinfectant sales(Free of Hazardous Chemicals);Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Chemical product production(No licensed chemical products).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Production of Class II Medical Devices;Class III Medical Device Leasing;Production of Class III Medical Devices;Class III medical device business;medical service;Internet Information Service for Medical Devices;Cosmetic production.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Oncotherapy science (OTS) is“ to deliver cancer therapeutics and treatments with higher efficacy and fewer side effects to patients suffering from cancer as soon as possible, and to overcome the fight against cancer. Was established with the aim of OTS brought Professor Genomix (Science that handles genetic information systematically) as a pioneer in the medical field with Prof. Atsushi Nakamura (Director, Cancer Precision Medical Research Center, Institute of Cancer, Professor Emeritus, The University of Tokyo, Professor Emeritus of Chicago University) Joint research to identify target molecules suitable for cancer drug development based on comprehensive gene expression analysis, and promote research and development of small molecule drugs, cancer peptide vaccines and antibody drugs for those targets.

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.

Manufactures pharmaceuticals

R.P. Scherer Technologies LLC, a subsidiary of Catalent, Inc., is an American company that develops, manufactures and sells oral, topical, sterile and inhaled forms of drug delivery products.

Xencor provides protein engineering technology platforms in the biotechnology industry. Its products include antibody therapeutics, such as XmAb2513 for the treatment of relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma; XmAb5574, a humanized monoclonal antibody that targets the antigen CD19 for the treatment of B cell malignancies; XmAb5592 for the treatment of myeloma; and XmAb5871 and XmAb7195, which are humanized monoclonal antibodies for the treatment of asthma and allergy. The company’s products also include XPro protein therapeutics, such as XPro1595, a dominant-negative inhibitor for the treatment of multiple animal models of autoimmune and neuroinflammatory diseases.

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb® technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners.

Eureka Therapeutics, Inc. develops therapeutic monoclonal antibodies for cancer indication and treatment. It focuses on the discovery of fully-human antibody drugs for the treatment of cancer and utilizing its antibody drug discovery and engineering technologies, and advancing therapies for targeting previously inaccessible cancer antigens. The company was founded by Cheng Liu in 2006 and is headquartered in Emeryville, CA.

Aptamer Sciences, Inc. 1 Founded in April 2011 by the best aptamer experts in Korea under the banner of bio company. Based on the globally competitive Aptamer Technology Platform, they are an R & D-based bio venture company that develops innovative therapeutics and diagnostic technologies that are difficult to develop with protein and genome-based biomaterials. Comprehensive range of pressures from technology to effectively discover high-performance aptamers, to improve and optimize the found aptamers for application purposes, and to develop innovative aptamer new drugs and aptamer-based multi-index diagnostic technology. They are building a tamer technology platform.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.

ExcelMab develops a series of anti-tumor bispecific antibody drugs for cancer patients.

Sanofi A/S engages in the production of prescription drugs as well as participates in clinical trials of present and future products. It specializes in diabetes, oncology, multiple sclerosis, rare disease and cardio vascular illnesses. The company is headquartered in Copenhagen, Denmark.